Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, announced the launch of Tofacitinib Tablets, the generic equivalent of Xeljanz® by Pfizer, in the disease-modifying antirheumatic drug category.

This launch reflects Breckenridge's continued commitment to expanding access to essential therapies for patients living with chronic inflammatory conditions, where treatment continuity, affordability, and reliable supply play a critical role in long-term disease management.